Noah M. Hahn

ScholarGPS® ID: 50786443846300

Highly Ranked Scholar - Prior Five Years:

#14

Cisplatin

Affiliation

Johns Hopkins University, Baltimore, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

265

Predicted Citations

15,850

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder (journal article) Patel, Sunil H. \| Gabrielson, Andrew T. \| Chan, Sin \| Schwartz, Deborah \| Collins, Connie \| Singla, Nirmish \| Trock, Bruce \| Bivalacqua, Trinity J. \| Hahn, Noah \| Kates, Max R. Journal of Urology, volume 212, issue 1, pages 95-103 (2024). 10.1097/JU.0000000000003977 Cited by (2) \| Cite \| Source
Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience (journal article) Vlachou, Evangelia \| Johnson, Burles Avner \| McConkey, David \| Jing, Yuezhou \| Matoso, Andres \| Hahn, Noah M. \| Hoffman-Censits, Jean Frontiers in Oncology, volume 14 (2024). 10.3389/fonc.2024.1377842 Cite \| Source
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol (journal article) Rezaee, Michael E \| Mahon, Katherine M \| Trock, Bruce J \| Nguyen, The-Hung Edward \| Smith, Armine K \| Hahn, Noah M \| Patel, Sunil H \| Kates, Max BMJ Open, volume 14, issue 6, pages e076763- (2024). 10.1136/bmjopen-2023-076763 Cite \| Source
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin (journal article) Vlachou, Evangelia \| Mamtani, Ronac \| Hahn, Noah M. \| Johnson, Burles \| Hoffman-Censits, Jean \| Nimgaonkar, Vivek Clinical Genitourinary Cancer, volume 22, issue 3, pages 102090- (2024). 10.1016/j.clgc.2024.102090 Cite \| Source
ERAS FOR AMBULATORY TURBT: ENHANCING BLADDER CANCER CARE (EMBRACE) RANDOMIZED CONTROLLED TRIAL (journal article) Rezaee, Michael E. \| Rodriguez-Mahon, Katherine \| Trock, Bruce J. \| Nguyen, The-Hung Edward \| Smith, Armine K. \| Hahn, Noah M. \| Patel, Sunil H. \| Kates, Max Urologic Oncology: Seminars and Original Investigations, volume 42 (2024). 10.1016/j.urolonc.2024.01.163 Cite \| Source
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction. (journal article) Shore, Neal D. \| Nishiyama, Hiroyuki \| Shariat, Shahrokh F. \| Steinberg, Gary \| Kamat, Ashish M. \| Alanee, Shaheen Riadh \| Nam, Kijoeng \| Imai, Kentaro \| Kapadia, Ekta \| Hahn, Noah M. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages TPS722-TPS722 (2024). 10.1200/JCO.2024.42.4_suppl.TPS722 Cite \| Source
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC). (journal article) Vlachou, Evangelia \| Elias, Roy \| Hahn, Noah M. \| McConkey, David James \| Johnson, Burles Avner \| Hoffman-Censits, Jean H. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 570-570 (2024). 10.1200/JCO.2024.42.4_suppl.570 Cited by (1) \| Cite \| Source
Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience. (journal article) Vlachou, Evangelia \| Johnson, Burles Avner \| Elias, Roy \| Hahn, Noah M. \| McConkey, David James \| Hoffman-Censits, Jean H. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 569-569 (2024). 10.1200/JCO.2024.42.4_suppl.569 Cited by (1) \| Cite \| Source
Evaluating outcomes of sacituzumab govitecan (SG) in patients with urothelial cancer (UC), previously treated with enfortumab vedotin (EV). (journal article) Vlachou, Evangelia \| Johnson, Burles Avner \| Hahn, Noah M. \| Rourke, Kelli \| McConkey, David James \| Hoffman-Censits, Jean H. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 567-567 (2024). 10.1200/JCO.2024.42.4_suppl.567 Cited by (1) \| Cite \| Source
Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts. (journal article) Vlachou, Evangelia \| Mamtani, Ronac \| Hahn, Noah M. \| Johnson, Burles Avner \| Hoffman-Censits, Jean H. \| Nimgaonkar, Vivek Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 544-544 (2024). 10.1200/JCO.2024.42.4_suppl.544 Cited by (1) \| Cite \| Source
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma (journal article) Hoffman-Censits, Jean \| Grivas, Petros \| Powles, Thomas \| Hawley, Jessica \| Tyroller, Karin \| Seeberger, Sonja \| Guenther, Silke \| Jacob, Natalia \| Mehr, Keyvan Tadjalli \| Hahn, Noah M Future Oncology, volume 20, issue 4, pages 179-190 (2024). 10.2217/fon-2023-0492 Cited by (2) \| Cite \| Source
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy (journal article) Grivas, Petros \| Koshkin, Vadim S. \| Chu, Xiangying \| Cole, Suzanne \| Jain, Rohit K. \| Dreicer, Robert \| Cetnar, Jeremy P. \| Sundi, Debasish \| Gartrell, Benjamin A. \| Galsky, Matthew D. \| ... \| Carducci, Michael A. European Urology Oncology (2023). 10.1016/j.euo.2023.11.022 Cited by (1) \| Cite \| Source
Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection (journal article) Meeks, Joshua J. \| Black, Peter C. \| Galsky, Matthew \| Grivas, Petros \| Hahn, Noah M. \| Hussain, Syed A. \| Milowsky, Matthew I. \| Steinberg, Gary D. \| Svatek, Robert S. \| Rosenberg, Jonathan E. European Urology, volume 84, issue 5, pages 473-483 (2023). 10.1016/j.eururo.2023.05.011 Cited by (14) \| Cite \| Source
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer (journal article) Anker, Jonathan \| Pal, Sumanta K \| Kim-Schulze, Seunghee \| Wang, Huan \| Halperin, Rebecca \| Uzilov, Andrew \| Imai, Naoko \| Eikawa, Shingo \| Saito, Takuro \| Sebra, Robert \| ... \| Galsky, Matthew D Journal for ImmunoTherapy of Cancer, volume 11, issue 8, pages e007613- (2023). 10.1136/jitc-2023-007613 Cited by (5) \| Cite \| Source
Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small‐cell carcinoma of the bladder (journal article) Parimi, Vamsi \| Choi, Woonyoung \| Feng, Mingxiao \| Fong, Megan \| Hoffman‐Censits, Jean \| Kates, Max \| Lombardo, Kara A. \| Comperat, Eva \| McConkey, David J. \| Hahn, Noah M. \| ... \| Matoso, Andres Histopathology, volume 82, issue 7, pages 991-1002 (2023). 10.1111/his.14883 Cited by (2) \| Cite \| Source
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer (journal article) Inman, Brant A. \| Hahn, Noah M. \| Stratton, Kelly \| Kopp, Ryan \| Sankin, Alex \| Skinner, Eila \| Pohar, Kamal \| Gartrell, Benjamin A. \| Pham, Song \| Rishipathak, Deepali \| ... \| Steinberg, Gary D. European Urology Oncology, volume 6, issue 3, pages 313-320 (2023). 10.1016/j.euo.2023.01.013 Cited by (10) \| Cite \| Source
Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature (journal article) Vlachou, Evangelia \| Matoso, Andres \| McConkey, David \| Jing, Yuezhou \| Johnson, Burles Avner \| Hahn, Noah M. \| Hoffman-Censits, Jean European Urology Open Science, volume 49 (2023). 10.1016/j.euros.2023.01.002 Cited by (12) \| Cite \| Source
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial. (journal article) Patel, Sunil H. \| Gabrielson, Andrew \| Collins, Connie \| Singla, Nirmish \| Bivalacqua, Trinity \| Hahn, Noah M. \| Kates, Max R. Journal of Clinical Oncology, volume 41, issue 6_suppl, pages 507-507 (2023). 10.1200/JCO.2023.41.6_suppl.507 Cited by (1) \| Cite \| Source
Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC). (journal article) Anker, Jonathan Forrest \| Pal, Sumanta Monty \| Kim-Schulze, Seunghee \| Wang, Huan \| Halperin, Rebecca \| Uzilov, Andrew \| Saito, Takuro \| Hahn, Noah M. \| Patel, Manishkumar \| Qi, Jingjing \| ... \| Galsky, Matt D. Journal of Clinical Oncology, volume 41, issue 6_suppl, pages 536-536 (2023). 10.1200/JCO.2023.41.6_suppl.536 Cite \| Source
Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience. (journal article) Vlachou, Evangelia \| Hahn, Noah M. \| Dabb, Alix \| Johnson, Burles Avner \| Lefande, M. Susan \| Hoffman-Censits, Jean H. Journal of Clinical Oncology, volume 41, issue 6_suppl, pages 523-523 (2023). 10.1200/JCO.2023.41.6_suppl.523 Cited by (2) \| Cite \| Source

Title	Investigators	Year	Cost	Agency
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)	Hahn, Noah M	2020	$656,816	NATIONAL CANCER INSTITUTE
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)	Hahn, Noah M	2019	$656,816	NATIONAL CANCER INSTITUTE